Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy.
HIV-infected children had a lower seroconversion rate to hepatitis B immunization and a more rapid antibody decline when compared to healthy children. Whether re-immunization or additional booster dose is necessary after immune recovery remains unknown. This study was conducted to determine the prevalence of hepatitis B virus protective antibody in HIV-infected children with immune recovery after highly active antiretroviral therapy (HAART). Serum hepatitis B viral markers were measured. An antibody level of > or =10 mIU/mL was defined as a protective antibody level. Only one out of 69 children (1%) had a protective antibody level. We concluded that despite the history of hepatitis B immunization and despite evidence of immune recovery after HAART, most HIV-infected children are still susceptible to HBV infection.
Siriaksorn
Sudawan
S
Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Puthanakit
Thanyawee
T
Sirisanthana
Thira
T
Sirisanthana
Virat
V
D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D002648:Child; D003430:Cross-Sectional Studies; D004198:Disease Susceptibility; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D006509:Hepatitis B / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000097:blood* / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D008297:Male; D012367:RNA, Viral / Q000097:blood
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D012367:RNA, Viral